Research / RMR / Fundamental state Inspectable configuration
State dimensions Filing 0001644378-26-000020 General Corporate
Operating cash generation 87th Own-history percentile · N=15
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
51.33% · OPTIONAL · VALID
Revenue growth 64th Own-history percentile · N=11
Evidence method Yoy · gp.fundamentals.revenue
3.31% · CORE · VALID
Operating margin 0th Own-history percentile · N=15
Evidence method Level · gp.fundamentals.operating_margin
-20.37% · CORE · VALID
SBC intensity 100th Own-history percentile · N=15
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
12.39% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 12 states History building
Sep 30, 2023 0/5 normalized Level 3 Dec 31, 2023 0/6 normalized Level 3 Mar 31, 2024 0/6 normalized Level 3 Jun 30, 2024 0/6 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 3/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 3 Period transition
What moved in the state? Cash Generation Decreased
Previous 116.16%
Current 51.33%
Delta -64.83% Growth Increased
Previous -7.63%
Current 3.31%
Delta 10.94% Profitability Decreased
Previous 16.75%
Current -20.37%
Delta -37.12% Sbc Intensity Increased
Previous 7.20%
Current 12.39%
Delta 5.19% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.